Edwards Lifesciences - A Fine Enterprise

BATS:EW   Edwards Lifesciences Corporation

How to summarize this business ?

Rising earnings with high profit margins and low debt over long period of time.

EPS has grown from 0.3 in 2010 to 2.48 in 2022, with average profit margin of 22% for the past 7 years. Equity has been growing from 1.9 in 2010 to 9.5 in 2022 (book value per share). For the past 7 years highest Debt to Equity was 0.35 in 2017, currently standing at 0.12 ;

Sales per share have been on a steady rise from 2 in 2010 to 8.6 in 2022.

Company handles cash very well with free cash flow being around the level of net income for most years.

At these market levels with current EPS, company has not been valued so low since 2015, making it an attractive offer for this kind of enterprise.

Have A Great Day.

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.